[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334880-105":59,"doc-detail-334880-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","deep-reinforcement-learning-identifies-personalized-intermittent-androgen-deprivation-therapy-for-prostate-cancer","Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer","","Drug resistance undermines androgen deprivation therapy by driving treatment failure and tumor progression. Intermittent androgen deprivation therapy (IADT) can leverage intratumoral competition between responsive and resistant cell populations, yet conventional IADT is population-based and uses prostate-specific antigen thresholds that are not optimized for individuals. A data-driven two-step approach develops a time-varied mixed-effect generative Lotka–Volterra model and an IADT framework (I2ADT) using reinforcement learning to learn patient-specific dynamics and optimal policies, prolonging progression time with reduced cumulative dosage.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deep-reinforcement-learning-identifies-personalized-intermittent-androgen-deprivation-therapy-for-prostate-cancer/334880/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deep-reinforcement-learning-identifies-personalized-intermittent-androgen-deprivation-therapy-for-prostate-cancer/334880.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does androgen deprivation therapy often fail in prostate cancer?","Question",{"text":112,"@type":113},"Resistance develops over time, leading to treatment failure and tumor progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problem does the proposed individualized IADT method address?",{"text":117,"@type":113},"It accounts for patient heterogeneity and avoids relying on predetermined prostate-specific antigen thresholds by learning optimal pause and resume policies from patient data.",{"name":119,"@type":110,"acceptedAnswer":120},"How does I2ADT improve treatment outcomes?",{"text":121,"@type":113},"Experiments with clinical trial data show it significantly prolongs time to progression while reducing cumulative drug dosage, and pilot trial validation supports its efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334880,1790177651,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Briefings in Bioinformatics, 2024, 25(2), bbae071  \n[https://doi.org/10.1093/bib/bbae071](https://doi.org/10.1093/bib/bbae071)  \nProblem Solving Protocol  \nDeep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer  \nYitao Lu, Qian Chu, Zhen Li, Mengdi Wang, Robert Gatenby and Qingpeng Zhang  \nCorresponding author: P307J, Graduate House, HKU, HK 00001, China. Tel.: +852-39179024; Fax: +852-28170859; E-mail: qpzhang@hku.hk  \nAbstract  \nThe evolution of drug resistance leads to treatment failure and tumor progression. Intermittent androgen deprivation therapy (IADT) helps responsive cancer cells compete with resistant cancer cells in intratumoral competition. However, conventional IADTis population-based, ignoring the heterogeneity of patients and cancer. Additionally, existing IADT relies on pre-determined thresholds of prostate-specific antigen to pause and resume treatment, which is not optimized for individual patients. To address these challenges, we framed a data-driven method in two steps. First, we developed a time-varied, mixed-effect and generative Lotka–Volterra (tM-GLV) model to account for the heterogeneity of the evolution mechanism and the pharmacokinetics of two ADT drugs Cyproterone acetate and Leuprolide acetate for individual patients. Then, we proposed a reinforcement-learning-enabled individualized IADT framework, namely, I2ADT, to learn the patient-specific tumor dynamics and derive the optimal drug administration policy. Experiments with clinical trial data demonstrated that the proposed I2ADT can significantly prolong the time to progression of prostate cancer patients with reduced cumulative drug dosage. We further validated the efficacy of the proposed methods with a recent pilot clinical trial data. Moreover, the adaptability of I2ADT makes it a promising tool for other cancers with the availability of clinical data, where treatment regimens might need to be individualized based on patient characteristics and disease dynamics. Our research elucidates the application of deep reinforcement learning to identify personalized adaptive cancer therapy.  \nKeywords: Adaptive therapy; Prostate cancer; Personalized medicine; Reinforcement learning  \nINTRODUCTION  \nProstate tumor is the second most prevalent cancer and the sixth leading cause of cancer death worldwide [1 , 2] . The common treatments of locally advanced prostate cancer are radiotherapy and hormone therapy [3 , 4] . Hormone therapy, such as androgen deprivation therapy (ADT), is an effective treatment and is usually applied after the failure of radiotherapy [5 , 6] . Similar to other hormone therapies, ADT has side effects, including decreased libido, impotence, hot flashes and sexual effects [7 , 8] .  \nThe difficulty in treating prostate cancer lies in the development of resistance, which usually leads to treatment failure and tumor progression [8 , 9] . There are multi-type cancer cells competing for resources in the resource-limited tumor  \nmicroenvironment. Such Darwinian dynamics can lead to a rapid proliferation of resistant population. In the conventional drug administration policy, the use of maximum tolerated dose until progression can give the resistant phenotype an advantage over the other competitors, leading to the faster development of tumor resistance [8] . Thus, the intermittent androgen deprivation therapy (IADT) was proposed and validated in several clinical trials especially for patients in phase 1b / phase 2 [6 , 10] .  \nFigure 1 illustrates the idea of ADT (a) and IADT (b) separately. If a maximum tolerated dose is adopted, the resistant phenotype has an evolutionary advantage over the responsive phenotypes, leading to quick tumor resistance to ADT (shown in Figure 1a) . IADT involves the intermittent administration of drugs, which  \nYitao Lu is currently a PhD student with the School of Data Science at the City University of Hong Kong. His research interests lie in the app","cbCaitfA1TFXHu6i","https://ap.wps.com/l/cbCaitfA1TFXHu6i","pdf",1937743,12,"English","# Introduction\n## Prostate cancer and hormone therapy\n## Resistance and rationale for IADT","[{\"question\":\"Why does androgen deprivation therapy often fail in prostate cancer?\",\"answer\":\"Resistance develops over time, leading to treatment failure and tumor progression.\"},{\"question\":\"What problem does the proposed individualized IADT method address?\",\"answer\":\"It accounts for patient heterogeneity and avoids relying on predetermined prostate-specific antigen thresholds by learning optimal pause and resume policies from patient data.\"},{\"question\":\"How does I2ADT improve treatment outcomes?\",\"answer\":\"Experiments with clinical trial data show it significantly prolongs time to progression while reducing cumulative drug dosage, and pilot trial validation supports its efficacy.\"}]","Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer | PDF",1790008725]